MX2023004428A - Complejos radioactivos de anticuerpo anti-her2 y radiofarmaceutico. - Google Patents

Complejos radioactivos de anticuerpo anti-her2 y radiofarmaceutico.

Info

Publication number
MX2023004428A
MX2023004428A MX2023004428A MX2023004428A MX2023004428A MX 2023004428 A MX2023004428 A MX 2023004428A MX 2023004428 A MX2023004428 A MX 2023004428A MX 2023004428 A MX2023004428 A MX 2023004428A MX 2023004428 A MX2023004428 A MX 2023004428A
Authority
MX
Mexico
Prior art keywords
her2 antibody
radiopharmaceutical
conjugate
chelating agent
radioactive complexes
Prior art date
Application number
MX2023004428A
Other languages
English (en)
Spanish (es)
Inventor
Takahisa Hanada
Gota Tonoya
Minoru KAWATANI
Takuya Takeda
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of MX2023004428A publication Critical patent/MX2023004428A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/244Lanthanides; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023004428A 2020-10-16 2021-10-15 Complejos radioactivos de anticuerpo anti-her2 y radiofarmaceutico. MX2023004428A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020174840 2020-10-16
JP2020215740 2020-12-24
JP2021024688 2021-02-18
PCT/JP2021/038207 WO2022080481A1 (ja) 2020-10-16 2021-10-15 抗her2抗体の放射性複合体、及び、放射性医薬

Publications (1)

Publication Number Publication Date
MX2023004428A true MX2023004428A (es) 2023-05-04

Family

ID=81208085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004428A MX2023004428A (es) 2020-10-16 2021-10-15 Complejos radioactivos de anticuerpo anti-her2 y radiofarmaceutico.

Country Status (10)

Country Link
US (1) US20230390425A1 (https=)
EP (1) EP4230637A4 (https=)
JP (1) JPWO2022080481A1 (https=)
KR (1) KR20230088764A (https=)
AU (1) AU2021361746A1 (https=)
CA (1) CA3198721A1 (https=)
IL (1) IL302111A (https=)
MX (1) MX2023004428A (https=)
TW (1) TW202233247A (https=)
WO (1) WO2022080481A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES3058443T3 (es) 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
DK3470418T3 (da) * 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
JP7291395B2 (ja) 2017-06-16 2023-06-15 国立大学法人 鹿児島大学 IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾
BR112020012099A2 (pt) * 2017-12-18 2020-11-17 Janssen Biotech, Inc. radiomarcação de polipeptídeos
SG11202009990UA (en) * 2018-04-16 2020-11-27 Nihon Mediphysics Co Ltd Modified antibody and radioactive metal-labelled antibody
JP2020021574A (ja) 2018-07-30 2020-02-06 パナソニックIpマネジメント株式会社 光源ユニット、照明器具、及び照明器具用の拡張構造
JP2020174840A (ja) 2019-04-17 2020-10-29 豊丸産業株式会社 遊技機
JP7272895B2 (ja) 2019-08-02 2023-05-12 清水建設株式会社 水平搬送台車
IL292133A (en) * 2019-10-18 2022-06-01 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
JPWO2021075546A1 (https=) * 2019-10-18 2021-04-22
TWI886164B (zh) 2019-10-24 2025-06-11 國立大學法人鹿兒島大學 1價ccap生成物之製造方法
WO2022149578A1 (ja) * 2021-01-08 2022-07-14 日本メジフィジックス株式会社 Ac-225溶液の製造方法およびAc-225溶液を用いた医薬の製造方法
EP4397320A1 (en) * 2021-08-31 2024-07-10 Nihon Medi-Physics Co., Ltd. Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product

Also Published As

Publication number Publication date
EP4230637A1 (en) 2023-08-23
US20230390425A1 (en) 2023-12-07
IL302111A (en) 2023-06-01
WO2022080481A1 (ja) 2022-04-21
EP4230637A4 (en) 2025-12-17
KR20230088764A (ko) 2023-06-20
AU2021361746A1 (en) 2023-06-22
CA3198721A1 (en) 2022-04-21
AU2021361746A9 (en) 2024-06-27
TW202233247A (zh) 2022-09-01
JPWO2022080481A1 (https=) 2022-04-21

Similar Documents

Publication Publication Date Title
PE20220935A1 (es) Quelantes macrociclicos y metodos de uso de estos
ES8404857A1 (es) Un procedimiento para preparar un anticuerpo monoclonal para un antigeno asociado a un tumor.
CL2010000791A1 (es) Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)
MX2019010206A (es) Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
MX9307044A (es) Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos.
CO2023004110A2 (es) Anticuerpos anti-fgfr2 y métodos para usarlos
WO2023191839A3 (en) Stabilized compositions of radionuclides and uses thereof
CO6270369A2 (es) Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas
RU2008141171A (ru) Анти-тат226 антитела и иммуноконъюгаты
MX347883B (es) Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
ES2533963T3 (es) Composiciones farmacéuticas dirigidas a receptores Erb-B1
AR085874A2 (es) Un anticuerpo monoclonal o un fragmento del mismo que se une a un antigeno
MX2022004582A (es) Anticuerpo humanizado marcado con ri.
HRP20030805B1 (hr) Rekombinantna protutijela povezana s gangliozidima i njihova upotreba u dijagnostici i liječenju tumora
Thakral et al. An approach for conjugation of 177Lu-DOTA-SCN-Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
CO2023016712A2 (es) Conjugados de neodegradador-anticuerpo anti-cd33
ATE196477T1 (de) Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
CO2025007425A2 (es) Derivados de exatecan y conjugados de anticuerpo y fármaco de estos
CO2024003299A2 (es) Conjugado anticuerpo-fármaco anti-cd37
MX2023004428A (es) Complejos radioactivos de anticuerpo anti-her2 y radiofarmaceutico.
ES2114547T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c.
ZA202305253B (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
MX2022009138A (es) Anticuerpos y fragmentos de anticuerpos anti-her2 condicionalmente activos, sus inmunoconjugados y usos de estos.
PE52996A1 (es) FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO